Trial Profile
A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Estramustine (Primary) ; Exisulind (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Sep 2009 New trial record